BioGene Therapeutics Welcomes Professor Mirela Delibegovic, FRSE to Its Scientific Advisory Board
Vancouver, British Columbia--(Newsfile Corp. - November 21, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. has appointed Prof. Mirela Dellbegovic, FRSE to the Scientific Advisory Board effective on 19...
2024-11-21 7:00 AM EST
PreveCeutical's Subsidary, Biogene Therapeutics Announces Strategic Appointments: Dr. Linnea Olofsson as Chief Scientific Officer and Dr. Harry Parekh as Chief Research Officer
Vancouver, British Columbia--(Newsfile Corp. - November 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly owned subsidiary BioGene Therapeutics Inc. announce the appointments of Dr. Linnea Olofsson as Chief Scientific Officer (CSO) and Dr. Harry...
2024-11-18 7:00 AM EST
PreveCeutical Announces Closing of BioGene Therapeutics Transaction
Vancouver, British Columbia--(Newsfile Corp. - November 15, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that, further to its news release dated October 30, 2024, PreveCeutical has closed the intellectual property asset sale transaction ("Transaction") among its...
2024-11-15 2:49 PM EST
PreveCeutical's Subsidiary, BioGene Therapeutics, Appoints President
Vancouver, British Columbia--(Newsfile Corp. - November 13, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that its wholly-owned subsidiary BioGene Therapeutics Inc. has appointed Dr. Mariya Georgieva as President effective on 11 November, 2024. Stephen Van Deventer,...
2024-11-13 7:00 AM EST
PreveCeutical Launches Strategic Partnership with BioGene Therapeutics
Vancouver, British Columbia--(Newsfile Corp. - October 30, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE:18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that it has signed a definitive agreement on the 29 October, 2024 (the "Agreement") to sell certain intellectual property assets (the "Assets") owned by itself...
2024-10-30 6:30 AM EDT
PreveCeutical Engages Phoenix Corporate Finance Inc. to Provide Advisory Services
Vancouver, British Columbia--(Newsfile Corp. - October 18, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical" or the "Company"), a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature-identical products, is pleased to announce that it has engaged Toronto-based Phoenix Corporate Finance Inc. ("Phoenix") as its advisory firm to provide strategic and corporate advisory services relating...
2024-10-18 2:46 PM EDT
PreveCeutical Engages Outside The Box Capital Inc. to Provide Marketing Services
Vancouver, British Columbia--(Newsfile Corp. - September 3, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it has entered into a Marketing Service Agreement dated effective September 1, 2024 (the "Agreement") with Outside the Box Capital Ltd. ("OTB"), whereby OTB will provide the Company with certain marketing services (the "Services"). As consideration for the Services, the Company will pay OTB a cash fee in the...
2024-09-03 7:00 AM EDT
Preveceutical Announces Revocation of Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - July 9, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to announce that, further to the Company's news release dated June 28, 2024, the Company has completed the filings of its interim financial statements, accompanying management's discussion and analysis and related CEO and CFO certificates for the period ended March 31, 2024 (the "Q1 Filings"). Accordingly, the management...
2024-07-09 7:00 AM EDT
PreveCeutical Provides Update on Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to announce that today it has filed its audited annual financial statements and accompanying management's discussion and analysis, with related CEO and CFO certificates, for the financial year ended December 31, 2023 (collectively, the "Annual Filings"). The Annual Filings are available on SEDAR+ as well as the CSE...
2024-06-28 6:17 PM EDT
PreveCeutical Enters into Loan Agreements
Vancouver, British Columbia--(Newsfile Corp. - June 17, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that it has entered into a series of unsecured, non-convertible and interest-free loan agreements with, the Company's Chief Executive Officer, interim Chief Financial Officer and Chair, Stephen Van Deventer, and the Company's former President and director, Kimberly Van Deventer (collectively, the "Lenders"), in the...
2024-06-17 4:22 PM EDT
PreveCeutical Provides Update on Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - June 14, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is providing an update with respect to the Management Cease Trade Order ("MCTO") issued by the British Columbia Securities Commission (the "BCSC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), effective as of May 2, 2024, and as previously announced by the Company. The MCTO was issued by the BCSC in...
2024-06-14 7:00 AM EDT
PreveCeutical Commences Litigation Against Former Legal Counsel in the British Columbia Supreme Court Alleging Professional Negligence
Vancouver, British Columbia--(Newsfile Corp. - June 6, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), announces that it, along with certain others, filed a Notice of Civil Claim (the "Claim") in the British Columbia Supreme Court on June 5, 2024 against its former legal counsel (the "Defendants"). The Claim alleges that the Defendants were negligent in the provision of legal advice in relation to the Company's issuance of a news...
2024-06-06 7:00 AM EDT
Preveceutical Provides Update on Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is providing an update with respect to the Management Cease Trade Order ("MCTO") issued by the British Columbia Securities Commission (the "BCSC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), effective as of May 2, 2024, and as previously announced by the Company. The MCTO was issued by the BCSC in...
2024-05-30 7:00 AM EDT
Preveceutical Announces First Tranche Closing of Private Placement
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is pleased to announce that further to its news release dated May 16, 2024, the Company has closed the first tranche of its non-brokered private placement (the "Private Placement") for gross proceeds of $115,000 through the sale of 4,600,000 units of the Company ("Units") at a price of $0.025 per Unit. Each Unit consists of one...
2024-05-29 7:11 PM EDT
PreveCeutical Provides Update on Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - May 16, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") is providing an update with respect to the Management Cease Trade Order ("MCTO") issued by the British Columbia Securities Commission (the "BCSC") under National Policy 12-203 - Management Cease Trade Orders ("NP 12-203"), effective as of May 2, 2024, and as previously announced by the Company. The MCTO was issued by the BCSC in...
2024-05-16 8:32 PM EDT
PreveCeutical Announces Management Cease Trade Order
Vancouver, British Columbia--(Newsfile Corp. - May 2, 2024) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that the Company has missed the filing deadline of April 29, 2024 to file the Company's audited annual financial statements and accompanying management's discussion and analysis, with related CEO and CFO certificates, for the financial year ended December 31, 2023 (collectively, the "Annual Filings"), as required under...
2024-05-02 6:36 PM EDT
PreveCeutical Files Two Family Patents of Sol-Gel Cannabinoid Formulation and Antiviral Use & Cyclic Peptides and Uses Thereof
Vancouver, British Columbia--(Newsfile Corp. - June 28, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that PreveCeutical is furthering the progress of two of its patent families. The patent family based on PCT/AU2021/051383 (P114915, Sol-gel cannabinoid formulation and antiviral use), has now entered the national phase in Europe and Australia. The Australian case has been allocated application no....
2023-06-28 7:00 AM EDT
PreveCeutical Medical - Sol-Gel and Uses thereof Patent Update
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2023) - PreveCeutical Medical Inc. (the "Company" or "PreveCeutical") (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H), is pleased to announce that PreveCeutical is furthering the progress of its patent family directed to Sol-Gel (International Patent Application No. PCT/AU2021/051383, Sol-Gel Cannabinoid Formulation and Antiviral Use) and is taking the International patent application forward in the US and Canada, with plans to progress in Europe...
2023-05-30 7:00 AM EDT
PreveCeutical Medical Launches Clinical Artificial Intelligence Division
Vancouver, British Columbia--(Newsfile Corp. - April 24, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that on April 21, 2023, PreveCeutical created a new division to develop and train an Artificial Intelligence (AI) tool that will be capable of learning R&D, clinical trials, and other clinical information. PreveCeutical plans to use this tool in the development and process of all our clinical programs. This...
2023-04-24 7:00 AM EDT
PreveCeutical Medical Announces Live Interactive Q&A Video Conference
Vancouver, British Columbia--(Newsfile Corp. - April 20, 2023) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that Stephen Van Deventer will be participating in a live interactive video conference Q&A forum on April 25, 2023. All participants are encouraged to pre-register to ensure access to the live virtual event and to submit any questions they may have prior to enable the producers to reduce duplications of...
2023-04-20 7:00 AM EDT